Santen Pharmaceutical Co., Ltd. American Depositary Receipt (SNPHY)
OTC
Closed
Oct 7, 2026
Day's Range
10.5952 wk Range
9.22Overview - SNPHY - Santen Pharmaceutical Co., Ltd. American Depositary Receipt
Key Statistics
Valuation
Enterprise Value
-479.53M
P/E (Trailing)
‪13.92‬
P/E (Forward)
‪14.49‬
PEG Ratio
‪1.73‬
Price / Sales (TTM)
‪0.01‬
Price / Book
‪1.80‬
EV / EBITDA
‪-1.16‬
Profitability
Profit Margin
‪13.25%‬
Operating Margin
‪11.77%‬
Return on Assets
‪7.09%‬
Return on Equity
‪13.42%‬
Ownership
Shares Outstanding
321.28M
Float
314.54M
Held by Insiders
‪0.00%‬
Held by Institutions
‪0.00%‬
Price stats
50-Day Avg
‪11.50‬
200-Day Avg
‪11.46‬
Dividends
Payout Ratio
‪31.87%‬
Frequency
Annual
Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - SNPHY - Santen Pharmaceutical Co., Ltd. American Depositary Receipt
Peers - SNPHY - Santen Pharmaceutical Co., Ltd. American Depositary Receipt
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on OTC.
- SNPHYOTCSanten Pharmaceutical Co., Ltd. American Depositary Receipt3.39BMarket Cap+2.17%52-week change13.92P/E (Trailing)‪13.25%‬Profit Margin
- RHHBYOTCRoche Holding AG351.59BMarket Cap+25.31%52-week change23.22P/E (Trailing)‪19.60%‬Profit Margin
- NVSEFOTCNovartis AG Registered Shares270.87BMarket Cap+11.61%52-week change21.26P/E (Trailing)‪22.50%‬Profit Margin
- NONOFOTCNovo Nordisk A/S171.32BMarket Cap-43.33%52-week change9.49P/E (Trailing)‪35.34%‬Profit Margin
- GLAXFOTCGSK plc97.17BMarket Cap+20.46%52-week change15.63P/E (Trailing)‪14.52%‬Profit Margin
- SNYNFOTCSanofi SA96.26BMarket Cap-30.80%52-week change21.31P/E (Trailing)‪8.09%‬Profit Margin
- CHGCYOTCChugai Pharmaceutical Co. Ltd.69.41BMarket Cap-1.33%52-week change23.18P/E (Trailing)‪35.10%‬Profit Margin
Profile Summary - SNPHY - Santen Pharmaceutical Co., Ltd. American Depositary Receipt
About
Santen Pharmaceutical Co., Ltd. American Depositary Receipt is a type of equity security that represents shares of Santen Pharmaceutical, a leading Japanese company focused on ophthalmology and related healthcare fields. This ADR allows investors in the United States to gain exposure to Santen Pharmaceutical's stock,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
